Novel Oral/Nasal Immunotherapy Platform: The company's pioneering development of orally and intranasally administered monoclonal antibodies, such as Foralumab, offers a unique and proprietary approach to treating autoimmune diseases that stands apart from traditional intravenous biologic therapies.

Enhanced Patient Convenience & Adherence: Non-invasive oral and intranasal routes of administration for its lead drug candidate Foralumab present significant advantages in patient comfort, ease of use, and potential for improved adherence, which can reduce the burden associated with infusion-based treatments.

Targeted Mucosal Immune Modulation: Foralumab's ability to engage the gut and nasal associated lymphoid tissues allows for precise immune re-balancing and induction of regulatory T cells (Tregs), potentially leading to superior efficacy and safety profiles by targeting the immune system where many autoimmune conditions originate.